A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia

非布索坦 黄嘌呤氧化酶抑制剂 高尿酸血症 药理学 黄嘌呤氧化酶 最大值 药代动力学 尿酸 化学 医学 内科学 生物化学
作者
Chenjing Wang,Qing Yu,Xin Jiang,Yujie Deng,Feifei Sun,Xin Li,Ye Tao,Pingping Lin,Yaping Ma,Yuxian Zhu,Chengqian Li,Yu Cao
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:63 (2): 239-249 被引量:6
标识
DOI:10.1002/jcph.2159
摘要

Abstract SHR4640 is a novel, selective urate reabsorption inhibitor. As the mode of action of SHR4640 differs from that of a xanthine oxidase inhibitor, such as febuxostat, coadministration of these drugs may be a treatment option for patients with primary hyperuricemia. We assessed the potential drug–drug interaction between SHR4640 and febuxostat. In this single‐center, open‐label, randomized, drug–drug interaction study, subjects received 80 mg febuxostat or 10 mg SHR4640 alone daily in the first week, whereas during the second week a combination of SHR4640 and febuxostat was administered daily to all subjects. Plasma concentrations of SHR4640 and febuxostat were analyzed. We compared their pharmacokinetic and pharmacodynamic parameters and assessed both safety and tolerability. Compared with febuxostat alone, the geometric mean ratios (90%CIs) of the maximum concentration (C max ) and the area under the plasma concentration–time curve over the dosing interval τ (AUC 0–τ ) for febuxostat after coadministration were 1.284 (1.016 to 1.621) and 0.984 (0.876 to 1.106), respectively. The geometric mean ratios (90%CIs) of C max and AUC 0–τ for SHR4640 after coadministration compared with SHR4640 alone were 0.910 (0.839 to 0.988) and 0.929 (0.893 to 0.966), respectively. Febuxostat had no effect on SHR4640 pharmacokinetic parameters, as the 90%CIs of the geometric mean ratios were all within the range of 0.80 to 1.25. The coadministration of febuxostat and SHR4640 was well tolerated. The coadministration of SHR4640 with febuxostat was not associated with any clinically relevant pharmacokinetic drug interactions. SHR4640 combined with febuxostat had a synergistic effect on reducing uric acid in the pharmacodynamics, with the AUC decreasing from 7440 to 3170 h μmol/L compared with febuxostat alone and from 5730 to 2960 h μmol/L compared with SHR4640 alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包应助害羞采萱采纳,获得10
刚刚
LordAsriel完成签到,获得积分10
刚刚
刚刚
fishh完成签到,获得积分10
刚刚
星星完成签到,获得积分10
1秒前
shuaishuyi完成签到,获得积分10
2秒前
酷炫的星星完成签到,获得积分10
2秒前
3秒前
zzz完成签到,获得积分10
3秒前
烛光完成签到,获得积分10
3秒前
lingzi1015完成签到,获得积分10
3秒前
复杂大地完成签到,获得积分20
3秒前
研友_La17wL完成签到,获得积分10
3秒前
复杂怜容发布了新的文献求助10
4秒前
4秒前
安澜发布了新的文献求助10
4秒前
Lucas应助IT小师弟采纳,获得10
5秒前
yxy999完成签到,获得积分10
5秒前
追寻依风完成签到,获得积分10
5秒前
5秒前
JamesPei应助Relaxing采纳,获得10
5秒前
小包子完成签到,获得积分10
5秒前
热心焦发布了新的文献求助10
6秒前
俊逸半青完成签到,获得积分10
6秒前
Imin发布了新的文献求助10
6秒前
6秒前
6秒前
大力一德完成签到,获得积分10
6秒前
7秒前
tlrelax完成签到,获得积分10
7秒前
Jaslin完成签到,获得积分10
7秒前
风车车完成签到,获得积分10
7秒前
今后应助眼睛大花生采纳,获得10
8秒前
coolru完成签到,获得积分0
8秒前
蒋若风发布了新的文献求助10
8秒前
JJJJJJ完成签到,获得积分10
8秒前
甜美的月饼完成签到,获得积分10
8秒前
9秒前
9秒前
无极微光应助LongY采纳,获得20
9秒前
高分求助中
Clinical Epidemiology: The Essentials, 6e 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Graphene Handbook (2019 Edition) 800
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6534918
求助须知:如何正确求助?哪些是违规求助? 8328197
关于积分的说明 17842078
捐赠科研通 5636603
什么是DOI,文献DOI怎么找? 2934644
邀请新用户注册赠送积分活动 1910857
关于科研通互助平台的介绍 1769279